Everotas 0.25mg Tablet

Everotas 0.25mg tablet is an antineoplastic drug from the mTOR kinase inhibitor class, containing everolimus as its active ingredient. It is indicated for advanced breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumours, and subependymal giant cell astrocytoma (tumours located in the brain ventricles). Maintenance of good oral hygiene and regular dental check-ups are important during treatment, as this medicine can cause mouth sores or ulcers. For subependymal giant cell astrocytoma, it is often used in combination with cyclophosphamide, an alkylating agent.

Before commencing treatment, patients should be aware that this medicine increases the risk of bacterial and viral infections. Patients with a history of Hepatitis B infection face increased risk of reinfection. Inform your healthcare provider if you develop fever, chills, cough, yellowing of skin, joint pain, or swelling during treatment. Limit sun and UV light exposure by wearing protective clothing and applying sunscreen regularly, as this medicine may elevate the risk of developing skin cancers. Do not consume grapefruit juice or grapefruit whilst taking this medicine. This tablet is not recommended for adolescents and children under 18 years of age.

Seek immediate medical attention if you experience shortness of breath, chest pain, or worsening cough. Your doctor may periodically check your white blood cell counts, platelets, blood sugar levels, electrolytes, and kidney function parameters to prevent serious complications. This medicine has the potential to cause kidney dysfunction. Report to your doctor if you have pre-existing liver disorders, heart failure, high cholesterol levels, or hypertension before starting treatment. Avoid live vaccines and close contact with individuals who have received live vaccines.

Advanced breast cancer Advanced renal cell carcinoma Advanced pancreatic neuroendocrine tumours Treatment of subependymal giant cell astrocytoma

Everotas 0.25mg tablet inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein and helps to reduce the size of tumours and improve outcomes in patients.

Take the Everotas 0.25mg tablet as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Difficulty breathing, or swallowing Swelling of face, lips, tongue, throat Severe itching, red rash, raised bumps Common Infection (chills, increased temperature) Coughing Wheezing Excessive thirst High urine output or severely decreased urine output Tiredness Bleeding Increased appetite with weight loss

Everotas 0.25mg tablet have the tendency to cause harm to the unborn foetus. Inform your healthcare provider before starting this treatment if you are pregnant, or planning for pregnancy. Your healthcare provider will conduct a pregnancy test before you start treatment with this drug. Discuss effective birth control methods with your healthcare provider and use them during the treatment for 8 weeks after your last dose. This medicine passes into breast milk. Hence, it is not recommended to breastfeed during this treatment. The occurrence of mouth ulcers or sores is pretty common during this treatment, so your healthcare provider will prescribe a mouthwash. Use the mouthwash as recommended which helps prevent and manage the symptoms.